Rigel pharmaceuticals: the overall objective of this contract is to evaluate the impact of fostamatinib treatment during hospitalization resulting from ards on long-term outcomes including clinical,…
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50123C00012
- Awardee
-
Rigel Pharmaceuticals Inc. UEI X7MHPBCMHFM3
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $749,999
Award facts
- Opportunity
-
- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement Solicitation · BAA20100SOL0002 · Posted Feb 3, 2020
- Contract value 100% obligated
- $749,999.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 100 offers Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- South San Francisco, CA 94080, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $749,999 |
About this award
This is a $749,999 firm-fixed-price contract awarded by the Office of the Assistant Secretary for Preparedness and Response (ASPR) to Rigel Pharmaceuticals Inc., a biopharmaceutical company focused on developing treatments for inflammatory, autoimmune, and viral diseases. The contract's objective is to evaluate the impact of Rigel's drug fostamatinib on long-term outcomes, including clinical, biomarker, imaging, quality of life, functional, and lung function measures, in patients hospitalized with Acute Respiratory Distress Syndrome (ARDS). The contract was awarded under a Broad Agency Announcement (BAA) solicitation issued by the Division of Research, Innovation, and Ventures (DRIVe) within ASPR's Biomedical Advanced Research and Development Authority (BARDA). This contract does not have a set-aside designation and is expected to be completed by October 31, 2025.
Description
Rigel pharmaceuticals: the overall objective of this contract is to evaluate the impact of fostamatinib treatment during hospitalization resulting from ards on long-term outcomes including clinical, biomarker, imaging, QOL, functional and lung functi
Quick answers
Who was awarded contract 75A50123C00012?
75A50123C00012 was awarded to Rigel Pharmaceuticals Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on May 1, 2023.
How much is contract 75A50123C00012 worth?
The government has obligated $749,999 on 75A50123C00012.
Was contract 75A50123C00012 competed?
The extent of competition for 75A50123C00012 was competed under sap. The government received 100 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award